XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory Board
March 23 2017 - 8:00AM
XBiotech Inc. (NASDAQ:XBIT) announced today that that Dr. Dirk
Arnold, a leading international specialist in gastrointestinal (GI)
cancers, has joined the Company’s Scientific Advisory Board (SAB).
Dr. Arnold will work with XBiotech to help navigate clinical
development and communicate the findings for the Company’s lead
product candidate in advanced colorectal cancer. Dr. Arnold’s
main research interests include the treatment of GI cancers with a
focus on targeted and immunotherapies, among others. Importantly,
his special interest in clinical research methodologies and benefit
evaluation are relevant to one of XBiotech’s lead oncology
programs, which has involved the development of a novel measure of
clinical efficacy in advanced cancer patients.
Dr. Arnold is a member of the following
organizations: Executive Board of the European Society for Medical
Oncology (ESMO) and European Cancer Organization
(ECCO); chairman of Colorectal Cancer Study Group of the
German Society of Clinical Oncology (AIO); American Society of
Clinical Oncology (ASCO); Task Force Colorectal Cancer of the
European Organization for Research and Treatment of Cancer (EORTC)
GI study group; German Cancer Society; and the German Society of
Haematology and Medical Oncology (DGHO). He is
currently Director of the Insituto CUF de Oncologia in Lisbon,
Portugal.
About True Human™ Therapeutic
AntibodiesXBiotech’s True Human™ antibodies are derived
without modification from individuals who possess natural immunity
to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human antibodies have the
potential to harness the body’s natural immunity to fight disease
with increased safety, efficacy and tolerability.
About XBiotech XBiotech is
a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information, visit
www.xbiotech.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024